In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
Doripenem 50% inhibitory concentrations (MIC50) and 90% inhibitory concentrations (MIC90) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa (n=200 strains), nonmucoid P. aeruginosa (n=200), and Burkholderia cepacia complex (n=200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 microg/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.
Chen
Yunhua
Y
Department of Pediatrics, Columbia University, 622 West 168th St., PH4W-470, New York, NY 10032, USA.
Garber
Elizabeth
E
Zhao
Qiuqu
Q
Ge
Yigong
Y
Wikler
Matthew A
MA
Kaniga
Koné
K
Saiman
Lisa
L
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019121:Burkholderia Infections / Q000382:microbiology; D042602:Burkholderia cepacia complex / Q000187:drug effects* / Q000302:isolation & purification; D015780:Carbapenems / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000382:microbiology*; D000077726:Doripenem; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000077726:Doripenem